サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：皮膚肥満細胞症治療薬の世界市場：成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149174

皮膚肥満細胞症治療薬の世界市場：成長、将来展望、競合分析（2022年～2030年）

Cutaneous Mastocytosis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
皮膚肥満細胞症治療薬の世界市場：成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月25日
発行: Acute Market Reports
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の皮膚肥満細胞症治療薬の市場規模は、2021年に2億3,027万米ドルとなり、2022年から2030年の予測期間中にCAGRで5.6％の成長が予測されています。市場を牽引している主な要因は、医師の疾患に対する意識の高まりが有病率の上昇につながり、皮膚肥満細胞症に対する標的特異的治療の研究開発の成長をさらに支援すると期待されています。

当レポートでは、世界の皮膚肥満細胞症治療薬市場について調査し、ミクロ・マクロ環境分析、市場動向、競合情報、セグメント分析、ポーターのファイブフォースモデル、主要投資市場：技術分析、ケーススタディ、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象読者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズI - 2次調査
    • フェーズII - 1次調査
    • フェーズIII - 専門家によるレビュー
    • 前提条件
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の皮膚肥満細胞症治療薬市場
  • 世界の皮膚肥満細胞症治療薬市場：薬剤クラス別（2021年）
  • 世界の皮膚肥満細胞症治療薬市場：地域別（2021年）
  • COVID-19の影響
  • 魅力的な投資提案：地域別（2021年）
  • 競合分析
    • 主要な皮膚肥満細胞症治療薬市場ベンダーの市場ポジショニング
    • 皮膚肥満細胞症治療薬市場のベンダーが採用する戦略
    • 主要な業界戦略

第3章 皮膚肥満細胞症治療薬市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 世界の皮膚肥満細胞症治療薬市場金額（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析

第4章 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 抗ヒスタミン剤
    • コルチコステロイド
    • 肥満細胞安定剤
    • 交感神経刺激薬（エピネフリン）
    • 光化学療法

第5章 北米の皮膚肥満細胞症治療薬市場（2020年～2030年）

  • 市場概要
  • 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）
  • 皮膚肥満細胞症治療薬市場：地域別（2020年～2030年）
    • 北米

第6章 英国・欧州連合の皮膚肥満細胞症治療薬市場（2020年～2030年）

  • 市場概要
  • 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）
  • 皮膚肥満細胞症治療薬市場：地域別（2020年～2030年）
    • 英国・欧州連合

第7章 アジア太平洋の皮膚肥満細胞症治療薬市場（2020年～2030年）

  • 市場概要
  • 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）
  • 皮膚肥満細胞症治療薬市場：地域別（2020年～2030年）
    • アジア太平洋

第8章 ラテンアメリカの皮膚肥満細胞症治療薬市場（2020年～2030年）

  • 市場概要
  • 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）
  • 皮膚肥満細胞症治療薬市場：地域別（2020年～2030年）
    • ラテンアメリカ

第9章 中東・アフリカの皮膚肥満細胞症治療薬市場（2020年～2030年）

  • 市場概要
  • 皮膚肥満細胞症治療薬市場：薬剤クラス別（2020年～2030年）
  • 皮膚肥満細胞症治療薬市場：地域別（2020年～2030年）
    • 中東・アフリカ

第10章 企業プロファイル

  • Pfizer Inc.
  • Merck & Co., Inc.
  • EPI Health, LLC.
  • kaleo, Inc.
  • Bausch Health Companies Inc.
  • Mylan N.V.
  • Sanofi
  • Mallinckrodt
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Johnson & Johnson
図表

List of Tables

  • TABLE 1 Global Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Latin America Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Cutaneous Mastocytosis Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Cutaneous Mastocytosis Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Cutaneous Mastocytosis Treatment Market: Quality Assurance
  • FIG. 5 Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Cutaneous Mastocytosis Treatment Market, By Geography, 2021
  • FIG. 7 Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Cutaneous Mastocytosis Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 138659-08-22

Industry Outlook

Cutaneous mastocytosis treatment market accounted for a market value of US$ 230.27 Mn in 2021 and is projected to grow at a CAGR of 5.6% during the forecast period from 2022 to 2030. Cutaneous mastocytosis is a rare disease in which uncontrolled production of mast cells leads to skin complications such as lesions, blisters, and rashes with aggravated itching. The key causes of cutaneous mastocytosis are a mutation in KIT gene which leads to overproduction of mast cells and excess accumulation of mast cell in the skin leads to chronic as well as acute reactions. The major factors that are driving this market are raising awareness related to the disease in physicians are assisting the growth of prevalence rate and expected to further assist the growth in research & development of target-specific treatment against cutaneous mastocytosis.

Photochemotherapy has satisfactory results and it is becoming choice of treatment for most of the dermatologists in developed as well as developing countries

Photochemotherapy (PUVA) is identified as the fastest growing segment throughout the forecast period from 2022 to 2030 due to an effective combination of drug Psoralens and long-wave ultraviolet radiation to treat cutaneous mastocytosis is accepted and practiced by several dermatologists from developed as well as developing countries. The patients initially exposed to psoralens, drugs that contain chemicals that react with ultraviolet light & later UVA light. However, Photochemotherapy sessions required for a patient suffering from cutaneous mastocytosis are in a range of 10 to 15 times in a month.

Asia Pacific is the fastest growing market due to rising awareness in dermatologists about the rare skin diseases and developing healthcare infrastructure in developing countries

During the forecast period from 2022 to 2030, Asia Pacific identified as the fastest growing cutaneous mastocytosis treatment market mainly due to increasing awareness in dermatologists related to rare genetic disorders, and developing healthcare infrastructure is assisting the diagnosis rate. Significant economic growth in developing & developed countries of Asia Pacific has increased the overall infrastructural development including healthcare, transport, educational, and others. This has led to increasing in opportunities for local as well as migrating individuals due to which population of Caucasians is also increasing in the Asia Pacific and as the study suggests that cutaneous mastocytosis observed mainly in Caucasians.

The key companies currently available in the market are analyzed based on recent market updates, product portfolio, financial data, and major strategies. This report also includes attractive investment proposition analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, and Mallinckrodt Pharmaceuticals among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cutaneous Mastocytosis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Cutaneous Mastocytosis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antihistamines
  • Corticosteroids
  • Mast Cell Stabilizers
  • Sympathomimetic Agents (Ephinephrine)
  • Photochemotherapy

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Cutaneous Mastocytosis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Cutaneous Mastocytosis Treatment market?
  • Which is the largest regional market for Cutaneous Mastocytosis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Cutaneous Mastocytosis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Cutaneous Mastocytosis Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Cutaneous Mastocytosis Treatment Market
  • 2.2. Global Cutaneous Mastocytosis Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Cutaneous Mastocytosis Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Cutaneous Mastocytosis Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Cutaneous Mastocytosis Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Cutaneous Mastocytosis Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Cutaneous Mastocytosis Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Antihistamines
    • 4.3.2. Corticosteroids
    • 4.3.3. Mast Cell Stabilizers
    • 4.3.4. Sympathomimetic Agents (Ephinephrine)
    • 4.3.5. Photochemotherapy

5. North America Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Cutaneous Mastocytosis Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Cutaneous Mastocytosis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Cutaneous Mastocytosis Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Pfizer Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Merck & Co., Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. EPI Health, LLC.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. kaleo, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Bausch Health Companies Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Mylan N.V.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Sanofi
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Mallinckrodt
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Bayer AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Novartis AG
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Johnson & Johnson
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives